About
Titles
Hospital Resident
Departments & Organizations
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Peter Podany's published research.
Publications Timeline
A big-picture view of Peter Podany's research output by year.
Malini Harigopal, MD
Liva Andrejeva-Wright, MD
Andrea Barbieri, MD
Uma Krishnamurti, MD, MBBS, PhD
Darin Dolezal, MD/PhD
Manju Prasad, MD, MBBS
14Publications
26Citations
Publications
2024
Complex Cystic and Solid Masses
Harigopal M, Cole K, Podany P, Verma A, Andrejeva L. Complex Cystic and Solid Masses. 2024, 57-95. DOI: 10.1007/978-3-031-65711-5_3.Peer-Reviewed Original ResearchConceptsCystic lesionsSolid massAspiration of cystsBenign papillary tumorsPapillary apocrine metaplasiaCore needle biopsyComplex cystic lesionsMalignant cystic lesionsPresence of calcificationLeakage of cyst contentsFindingsThe vast majorityPapillary tumorsApocrine carcinomaPapillary carcinomaDuctal carcinomaNipple dischargeCystic componentNeedle biopsyApocrine metaplasiaDuct ectasiaBenign lesionsReactive lesionsComplicated cystsPerimenopausal womenFat necrosisRare Breast Tumors
Harigopal M, Podany P, Andrejeva L, Singh K. Rare Breast Tumors. 2024, 343-374. DOI: 10.1007/978-3-031-65711-5_13.Peer-Reviewed Original ResearchConceptsSubtypes of breast cancerBreast cancerRare subtypeWorld Health OrganizationRare subtype of breast cancerHistological subtype of breast cancerWorld Health Organization Classification of TumorsCore needle biopsy specimensWorld Health Organization classificationTall cell carcinomaNeedle biopsy specimensRare histologic typeClassification of tumorsRare cancer typesRare tumorHistological subtypesHistological typeCell carcinomaUnusual subtypeBiopsy specimensPrognostic implicationsGenetic alterationsHistological featuresHistologic cluesAncillary testsCircumscribed Masses
Harigopal M, Raghu M, Pham R, Rende A, Podany P, Andrejeva L. Circumscribed Masses. 2024, 11-55. DOI: 10.1007/978-3-031-65711-5_2.Peer-Reviewed Original ResearchConceptsTerminal duct lobular unitsEncapsulated papillary carcinomaInvasive ductal carcinomaCircumscribed massFibroepithelial neoplasmsStromal componentsScreening mammographyPhyllodes tumorFibroepithelial lesionsPapillary carcinomaDuctal carcinomaInvasive carcinomaComplicated cystsCellular fibroadenomaHigh-grade invasive ductal carcinomaBI-RADSDuctal carcinoma in situOuter layer of myoepithelial cellsAggressive breast malignancyBasal-like carcinomasBenign fibroepithelial lesionsBenign fibroepithelial neoplasmBorderline phyllodes tumorMalignant phyllodes tumorSmooth muscle metaplasiaSpiculated Masses
Harigopal M, Andrejeva L, Lanjewar S, Podany P. Spiculated Masses. 2024, 127-158. DOI: 10.1007/978-3-031-65711-5_5.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaInvasive lobular carcinomaDuctal carcinoma in situLobular carcinomaDuctal carcinomaSpiculated massesTumor cellsBenign entitySclerosing adenosisCorrelation of imaging findingsDesmoplastic stromal responseDiscohesive tumor cellsCore needle biopsyPseudoangiomatous stromal hyperplasiaCarcinoma in situInvasive mammary carcinomaFalse-negative mammogramsGranular cell tumorInvasive tumor cellsDiabetic mastopathyMucinous carcinomaStromal hyperplasiaInvasive cancerPleomorphic calcificationsDesmoplastic stromaIntroduction and General Consideration of Radiology-Pathology Correlation
Harigopal M, Andrejeva L, Podany P, Lewin J, Raghu M, Singh K. Introduction and General Consideration of Radiology-Pathology Correlation. 2024, 1-9. DOI: 10.1007/978-3-031-65711-5_1.Peer-Reviewed Original ResearchConceptsFull-field digital mammographyInterval cancer rateIncreased cancer detection ratesCancer detection rateScreen-film mammographyCancer ratesBreast pathologistsYears of experiencePatient careNational expertsMultidisciplinary meetingComplex exerciseCore needle biopsyDiagnosis of breast lesionsDigital mammographyMammographyField of radiologyRadiology-pathology correlationTissue samplesRadiology reportsBreastAccurate diagnosis of breast lesionsCharacterization of lesionsBreast tissue samplesBreast imagingArchitectural Distortions
Butler R, Durand M, Lanjevar S, Podany P, Andrejeva L, Harigopal M. Architectural Distortions. 2024, 185-207. DOI: 10.1007/978-3-031-65711-5_7.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaLikelihood of malignancyRadial sclerosing lesionsLobular carcinomaSclerosing lesionsTubular carcinomaArchitectural distortionBenign entityDegree of proliferative changeRadial scar/complex sclerosing lesionDuctal carcinoma in situCarcinoma in situInvasive ductal carcinomaChance of malignancyIncidental microscopic findingAbsence of enhancementPost-contrast imagesMyoepithelial cell layerEntrapped glandsField digital mammographyDiscohesive cellsSonographic correlateDuctal carcinomaInvasive carcinomaPalpable massSkin Thickening and Vascular Lesions
Andrejeva L, Lanjewar S, Woolf G, Killelea B, Brownson K, Podany P, Harigopal M. Skin Thickening and Vascular Lesions. 2024, 297-323. DOI: 10.1007/978-3-031-65711-5_11.Peer-Reviewed Original ResearchConceptsRare group of neoplasmsInflammatory breast carcinomaInvasive lobular carcinomaMalignant vascular tumorsGroup of neoplasmsIll-defined marginsLobular carcinomaBreast carcinomaBenign tumorsClinical presentationBenign lesionsVascular tumorsBreast parenchymaClinical historyWell-circumscribedSkin thickeningMalignant processVascular lesionsRare groupImaging appearanceSubcutaneous tissueContrast enhancementBreastCarcinomaTumor
2023
HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience
Podany P, Golastani R, Zhan H, Liang Y, Harigopal M, Krishnamurti U. HER2 amplification in cases with low HER2 expression by immunohistochemistry (IHC): A Single Institutional Experience. American Journal Of Clinical Pathology 2023, 160: s9-s10. DOI: 10.1093/ajcp/aqad150.021.Peer-Reviewed Original ResearchCitationsConceptsLow HER2 expressionInvasive breast carcinomaIHC scoreHER2 expressionGroup 1Group 3HER2 immunohistochemistryHER2 testingGroup 2HER2 FISHGroup 4ASCO/CAP guidelinesGroup 5Single institutional experienceRecent clinical trialsStandard of careASCO/CAP 2018 guidelinesHER2/CEP17 ratioEquivocal HER2HER2 positivityTrastuzumab deruxtecanMore patientsCAP guidelinesPatient eligibilityCase reportPathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study
Zhan H, Fineberg S, Podany P, Zeng J, Wang Y, Harigopal M, Singh K. Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study. Human Pathology 2023, 142: 15-19. PMID: 37972873, DOI: 10.1016/j.humpath.2023.10.002.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNeoadjuvant endocrine therapyResidual tumour cellularityNeoadjuvant chemotherapyNeoadjuvant therapyMucinous carcinomaPathologic responseEndocrine therapyPathological responseMucin poolsBreast cancerEstrogen receptorTumor cellularityAcellular mucin poolsFavorable histologic subtypePreoperative adjuvant therapyRetrospective cohort studyComplete pathologic responseInvasive breast cancerNET groupMulti-institutional studyNeoadjuvant HER2Adjuvant therapyMC patientsCohort studyPathologic reviewBreast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review
Carrasco-Tenezaca F, Moreira-Dinzey J, Manrai P, Bearse M, Burela S, Podany P, Singh K, Pareja F, Zheng J, Muscato N, Liang Y, Zhan H, Krishnamurti U, Dolezal D, Wang J, Harigopal M. Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review. International Journal Of Surgical Pathology 2023, 32: 1037-1045. PMID: 37908113, DOI: 10.1177/10668969231209780.Peer-Reviewed Original ResearchConceptsBreast carcinomaTubulopapillary featuresHuman epidermal growth factor 2 (HER2) expressionBreast cancer histologic subtypesNonmetastatic breast carcinomaTriple-negative profileHigh-grade nuclear featuresTriple-negative carcinomasHigh-grade featuresMetastatic breast carcinomaGrowth factor 2 expressionFactor 2 expressionReports of tumorsMicropapillary projectionsNeoadjuvant therapyHistologic subtypeWorse prognosisFirst tumorPoor prognosisAdditional tumorsInvasive carcinomaEstrogen receptorCarcinomaPathogenic variantsTumors